FDA Okays Third Biosimilar of Avastin
Amneal's Alymsys is approved to treat several cancers.
The FDA has approved Amneal Pharmaceuticals’ biologics license application (BLA) for bevacizumab-maly, a biosimilar referencing Genentech’s Avastin. The product will be marketed under the name Alymsys.
Alymsys is a vascular endothelial growth factor inhibitor used in oncology. It is approved to treat metastatic colorectal cancer, non-squamous small cell lung cancer, recurrent gliobastoma, renal cell carcinoma, recurrent or metastatic cervical cancer, and epithelial ovarian cancer.
“Biosimilars represent the next wave of affordable medicines in the U.S. and are closely aligned with our strategy to provide high quality, affordable medicines to as many patients as possible,” Chirag and Chintu Patel, co-chief executive officers,” said in a press release.
Alymsys was developed in collaboration with mAbxience. This marks the second of three biosimilars approvals Amneal expects to receive this year in oncology. Alymsys was approved by the European Medicines Agency (EMA) in February 2021.
Earlier this year, Amneal received approval of Releuko (filgrastim-ayow), a filgrastim biosimilar referencing Neupogen. Ameal’s pegfilgrastim biosimilar referencing Neulasta is currently under review by the FDA.
Related: FDA Okays a Third Biosimilar to Neupogen
Two other Avastin biosimilars have been approved, including Amgen’s Mvasi (bevacizumab-awwb), which was approved in September 2017, and Pfizer’s Zirabev (bevacizumab-bvzr), which was approved in June 2019.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
